A Study of Safety and Efficacy of BTD-001 in Treatment of Patients With Idiopathic Hypersomnia (IH) or Narcolepsy Type 2

PHASE2CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 28, 2018

Study Completion Date

February 28, 2018

Conditions
Idiopathic HypersomniaNarcolepsy Without Cataplexy
Interventions
DRUG

BTD-001

DRUG

Placebo

Trial Locations (23)

10032

Columbia University Medical Center, New York

20815

The Center for Sleep and Wake Disorders, Chevy Chase

27612

Wake Research Associates, Raleigh

29201

SleepMed of South Carolina, Columbia

30329

Emory University School of Medicine Emory Sleep Center, Atlanta

30342

NeuroTrials Research Inc, Atlanta

31201

SleepMed of Central, Macon

33511

PAB Clinical Research, Brandon

33707

Clinical Research Group of St. Petersburg, St. Petersburg

35213

Sleep Disorders Center of Alabama, Birmingham

40218

Kentucky Research Group,, Louisville

45255

Community Research Management Assoc., Cincinnati

55109

Neurological Associate, Maplewood

63143

Clayton Sleep Institute, St Louis

73112

Lynn Institute, Oklahoma City

77063

Houston Sleep Center, Houston

78731

Future Search Trials of Neurology, Austin

80301

REM Sleep Medicine, Colorado Sleep Institute, Boulder

91786

Empire Clinical Research, Upland

92103

Pacific Research Network, San Diego

94304

Stanford Medicine Sleep Center, Palo Alto

98122

Swedish Medical Center, Seattle

02459

NeuroCare Center for Sleep, Newton

Sponsors
All Listed Sponsors
lead

Balance Therapeutics

INDUSTRY